314 related articles for article (PubMed ID: 26400847)
41. ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy.
Elizalde PV; Cordo Russo RI; Chervo MF; Schillaci R
Endocr Relat Cancer; 2016 Dec; 23(12):T243-T257. PubMed ID: 27765799
[TBL] [Abstract][Full Text] [Related]
42. Prediction of signaling cross-talks contributing to acquired drug resistance in breast cancer cells by Bayesian statistical modeling.
Azad AK; Lawen A; Keith JM
BMC Syst Biol; 2015 Jan; 9():2. PubMed ID: 25599599
[TBL] [Abstract][Full Text] [Related]
43. Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host.
Di Modica M; Tagliabue E; Triulzi T
Dis Markers; 2017; 2017():7849108. PubMed ID: 29403144
[TBL] [Abstract][Full Text] [Related]
44. Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications.
Rexer BN; Arteaga CL
Cancer Res; 2013 Jul; 73(13):3817-20. PubMed ID: 23794708
[TBL] [Abstract][Full Text] [Related]
45. Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin.
Campbell MR; Zhang H; Ziaee S; Ruiz-Saenz A; Gulizia N; Oeffinger J; Amin DN; Ahuja D; Moasser MM; Park CC
Breast Cancer Res Treat; 2016 Feb; 155(3):431-40. PubMed ID: 26860947
[TBL] [Abstract][Full Text] [Related]
46. Advances in EGFR/HER2-directed clinical research on breast cancer.
Chow LWC; Lie EF; Toi M
Adv Cancer Res; 2020; 147():375-428. PubMed ID: 32593406
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of the endosomal recycling pathway downregulates HER2 activation and overcomes resistance to tyrosine kinase inhibitors in HER2-positive breast cancer.
Mishra A; Hourigan D; Lindsay AJ
Cancer Lett; 2022 Mar; 529():153-167. PubMed ID: 35007696
[TBL] [Abstract][Full Text] [Related]
48. IL-8 secreted by tumor associated macrophages contribute to lapatinib resistance in HER2-positive locally advanced breast cancer via activation of Src/STAT3/ERK1/2-mediated EGFR signaling.
Ahmed S; Mohamed HT; El-Husseiny N; El Mahdy MM; Safwat G; Diab AA; El-Sherif AA; El-Shinawi M; Mohamed MM
Biochim Biophys Acta Mol Cell Res; 2021 May; 1868(6):118995. PubMed ID: 33667527
[TBL] [Abstract][Full Text] [Related]
49. Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began.
Meisel JL; Venur VA; Gnant M; Carey L
Am Soc Clin Oncol Educ Book; 2018 May; 38():78-86. PubMed ID: 30231395
[TBL] [Abstract][Full Text] [Related]
50. Targeted Therapy in HER2-Positive Breast Cancer.
Thill M; Kraft C; Friedrich M
Oncol Res Treat; 2016; 39(5):295-302. PubMed ID: 27173915
[TBL] [Abstract][Full Text] [Related]
51. Current and emerging therapies of HER2-positive metastatic breast cancer.
Hernández-Blanquisett A; Touya D; Strasser-Weippl K; Ruiz R; St Louis J; Goss P
Breast; 2016 Oct; 29():170-7. PubMed ID: 27526299
[TBL] [Abstract][Full Text] [Related]
52. Nuclear ErbB-2: a Novel Therapeutic Target in ErbB-2-Positive Breast Cancer?
Cordo Russo RI; Chervo MF; Madera S; Charreau EH; Elizalde PV
Horm Cancer; 2019 Jun; 10(2-3):64-70. PubMed ID: 30656558
[TBL] [Abstract][Full Text] [Related]
53. The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer.
Diver EJ; Foster R; Rueda BR; Growdon WB
Oncologist; 2015 Sep; 20(9):1058-68. PubMed ID: 26099744
[TBL] [Abstract][Full Text] [Related]
54. HER2-mediated anticancer drug delivery: strategies to prepare targeting ligands highly specific for the receptor.
Calce E; Monfregola L; Saviano M; De Luca S
Curr Med Chem; 2015; 22(21):2525-38. PubMed ID: 25994863
[TBL] [Abstract][Full Text] [Related]
55. Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?
Toss A; Venturelli M; Peterle C; Piacentini F; Cascinu S; Cortesi L
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28054957
[TBL] [Abstract][Full Text] [Related]
56. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer.
Jin Q; Esteva FJ
J Mammary Gland Biol Neoplasia; 2008 Dec; 13(4):485-98. PubMed ID: 19034632
[TBL] [Abstract][Full Text] [Related]
57. Therapeutic targeting of HER2-CB
Blasco-Benito S; Moreno E; Seijo-Vila M; Tundidor I; Andradas C; Caffarel MM; Caro-Villalobos M; Urigüen L; Diez-Alarcia R; Moreno-Bueno G; Hernández L; Manso L; Homar-Ruano P; McCormick PJ; Bibic L; Bernadó-Morales C; Arribas J; Canals M; Casadó V; Canela EI; Guzmán M; Pérez-Gómez E; Sánchez C
Proc Natl Acad Sci U S A; 2019 Feb; 116(9):3863-3872. PubMed ID: 30733293
[TBL] [Abstract][Full Text] [Related]
58. Signaling cross-talk in the resistance to HER family receptor targeted therapy.
Yamaguchi H; Chang SS; Hsu JL; Hung MC
Oncogene; 2014 Feb; 33(9):1073-81. PubMed ID: 23542173
[TBL] [Abstract][Full Text] [Related]
59. Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways.
Hatake K; Tokudome N; Ito Y
Breast Cancer; 2007; 14(2):132-49. PubMed ID: 17485898
[TBL] [Abstract][Full Text] [Related]
60. Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer.
Lv Q; Meng Z; Yu Y; Jiang F; Guan D; Liang C; Zhou J; Lu A; Zhang G
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27983617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
